Cell And Gene Therapy Market Size And Share

• A settembre 2023, Agilent Technologies Inc. ha firmato un Memorandum of Understanding (MOU) con l'Advanced Cell Therapy and Research Institute di Singapore (ACTRIS). Questo accordo mira a migliorare i progressi della terapia cellulare e genica nei prossimi tre anni.Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years.
• A marzo 2022, Cellevolve Bio ha stretto una partnership con Seattle Children's Therapeutics per sviluppare e commercializzare nuovi CAR multiplex per i tumori pediatrici. Con questa collaborazione, le aziende si concentreranno sul programma di ricerca BrainChild, una serie di cinque CAR multiplex, per curare le neoplasie maligne del sistema nervoso centrale (SNC) pediatriche. Mirano a sfruttare la struttura Cure Factory di Seattle Children's per condurre una ricerca clinica GMP precoce su nuovi CAR.Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program—a suite of five multiplex CARs—to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs.

1. Thermo Fisher Scientific, Inc.;
2. Merck KGaA;
3. Laboratori Charles River;
4. Catapulta per terapia cellulare e genica;
5. Lonza;
6. Azienda